Edition:
United Kingdom

Auris Medical Holding Ltd (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

2.71USD
23 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.71
Open
$2.81
Day's High
$2.81
Day's Low
$2.70
Volume
18,210
Avg. Vol
41,246
52-wk High
$39.20
52-wk Low
$2.42

Latest Key Developments (Source: Significant Developments)

Auris Medical Provides Update On Tinnitus Drug Development Strategy
Thursday, 25 Apr 2019 

April 25 (Reuters) - Auris Medical Holding Ltd ::AURIS MEDICAL PROVIDES UPDATE ON TINNITUS DRUG DEVELOPMENT STRATEGY.AURIS MEDICAL - INTENDS TO DISCUSS & VALIDATE PROTOCOL FOR CLINICAL TRIAL WITH ITS LATE-STAGE INVESTIGATIONAL DRUG KEYZILEN WITH FDA AND EMA.AURIS MEDICAL HOLDING - AIMS TO IMPLEMENT FURTHER DEVELOPMENT OF KEYZILEN AS WELL AS ITS EARLY-STAGE TINNITUS PROGRAMS WITH NON-DILUTIVE FUNDING.  Full Article

Auris Medical Holding AG Files Prospectus Relates To Resale Of Up To 10 mln Common Shares By LPC Capital Fund, Llc
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL HOLDING AG FILES FOR SECONDARY OFFERING OF UP TO 10 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.AURIS MEDICAL HOLDING AG FILES PROSPECTUS RELATES TO RESALE OF UP TO 10 MILLION COMMON SHARES OF CO BY SELLING SHAREHOLDER, LPC CAPITAL FUND, LLC.  Full Article

Auris Medical Secures Rights To In-License Additional Patents Related To Betahistine
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL ANNOUNCES ACQUISITION OF ORPHAN DRUG DESIGNATION AND SECURES RIGHTS TO IN-LICENSE ADDITIONAL PATENTS RELATED TO BETAHISTINE.AURIS MEDICAL - SIGNS LETTER OF INTENT TO IN-LICENSE TWO US PATENTS COVERING USE OF BETAHISTINE FOR TREATMENT OF DEPRESSION AND ATTENTION-DEFICIT.AURIS MEDICAL HOLDING AG - ACQUIRES ORPHAN DRUG DESIGNATION FOR BETAHISTINE FOR TREATMENT OF OBESITY ASSOCIATED WITH PRADER-WILLI SYNDROME.AURIS MEDICAL HOLDING AG - TWO TRANSACTIONS EXPECTED TO HAVE NO IMPACT ON CO'S DEVELOPMENT PLANS OR FINANCIAL POSITION IN NEAR-TERM.AURIS MEDICAL HOLDING AG - BETAHISTINE IS EXPECTED TO OFFER THERAPEUTIC BENEFITS ALSO IN TREATMENT OF ADHD AND ATYPICAL DEPRESSION.AURIS MEDICAL - BASED ON OUTCOMES FROM TRIALS AND DISCUSSIONS WITH HEALTH AUTHORITIES, PLANS TO INITIATE SPECIFIC DEVELOPMENTS IN NEW INDICATIONS.  Full Article

Auris Medical Holding Files For Offering Of Up To 1.75 Mln Common Shares By Lincoln Park Capital Fund
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL HOLDING AG FILES FOR OFFERING OF UP TO 1.75 MILLION CO'S COMMON SHARES BY LINCOLN PARK CAPITAL FUND LLC - SEC FILING.  Full Article

Auris Medical Holding AG Q3 Loss Per Share CHF 0.14
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE CHF 0.14.AURIS MEDICAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.CASH AND CASH EQUIVALENTS AT SEPT 30, 2018 TOTALED CHF 5.3 MILLION.CONTINUES TO EXPECT THAT OPERATING EXPENSES IN 2018 WILL BE IN RANGE OF CHF 10 TO 12.9 MILLION.  Full Article

Auris Medical Receives Positive Scientific Advice From EMA On Development Plan And Regulatory Pathway For AM-111
Monday, 7 May 2018 

May 7 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL RECEIVES POSITIVE SCIENTIFIC ADVICE FROM EMA ON DEVELOPMENT PLAN AND REGULATORY PATHWAY FOR AM-111.AURIS MEDICAL HOLDING AG - DESIGN FOR SINGLE PIVOTAL PHASE 3 TRIAL VALIDATED BY EUROPEAN MEDICINES AGENCY.AURIS MEDICAL - INTENDS TO PROVIDE UPDATE ON PLANS FOR ADVANCING AM-111 DEVELOPMENT PROGRAM AS PART OF A GENERAL STRATEGY UPDATE ON MAY 15.  Full Article

Auris Medical Announces Early Repayment Of Part Of Its Loan Facility
Monday, 9 Apr 2018 

April 9 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL ANNOUNCES EARLY REPAYMENT OF PART OF ITS LOAN FACILITY.REPAYMENT WILL RESULT IN SIGNIFICANT REDUCTION OF CO'S INTEREST EXPENSE.  Full Article

Auris Medical Q4 Loss Per Share CHF 0.10
Thursday, 22 Mar 2018 

March 22 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE CHF 0.10.COMPANY TO REVIEW STRATEGIC OPTIONS.COMPANY TO REVIEW STRATEGIC OPTIONS.‍PREPARING FOR HEALTH AUTHORITY DISCUSSIONS OF REGULATORY PATHWAY FOR AM-111 PROGRAM​.  Full Article

Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG - ON MARCH 12, AT THE GENERAL MEETING, SHAREHOLDERS APPROVED MERGER BETWEEN CO AND AURIS MEDICAL NEWCO - SEC FILING.AURIS MEDICAL HOLDING AG - CO'S SHAREHOLDERS RE-ELECTED THOMAS MEYER, , AS MEMBER AND CHAIRMAN OF THE BOARD OF DIRECTORS.  Full Article

Auris Medical Holding AG Files For Resale Of Up To 7.5 Mln Common Shares Issuable Upon Exercise Of Certain Outstanding Warrants
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG FILES FOR RESALE OF UP TO 7.5 MILLION COMMON SHARES ISSUABLE UPON EXERCISE OF CERTAIN OUTSTANDING WARRANTS - SEC FILING.  Full Article